Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) Gross Profit (2016 - 2025)

Historic Gross Profit for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $134.3 million.

  • Tandem Diabetes Care's Gross Profit rose 773.27% to $134.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $536.0 million, marking a year-over-year increase of 2599.7%. This contributed to the annual value of $489.6 million for FY2024, which is 3314.86% up from last year.
  • Latest data reveals that Tandem Diabetes Care reported Gross Profit of $134.3 million as of Q3 2025, which was up 773.27% from $125.9 million recorded in Q2 2025.
  • Tandem Diabetes Care's 5-year Gross Profit high stood at $157.5 million for Q4 2024, and its period low was $73.3 million during Q1 2021.
  • Moreover, its 5-year median value for Gross Profit was $101.9 million (2022), whereas its average is $106.6 million.
  • In the last 5 years, Tandem Diabetes Care's Gross Profit skyrocketed by 6998.35% in 2021 and then crashed by 1924.12% in 2023.
  • Over the past 5 years, Tandem Diabetes Care's Gross Profit (Quarter) stood at $113.7 million in 2021, then increased by 1.58% to $115.5 million in 2022, then decreased by 19.24% to $93.3 million in 2023, then skyrocketed by 68.77% to $157.5 million in 2024, then fell by 14.71% to $134.3 million in 2025.
  • Its Gross Profit stands at $134.3 million for Q3 2025, versus $125.9 million for Q2 2025 and $118.4 million for Q1 2025.